Carisma therapeutics, inc. CARM.US Overview
CARM AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
CARM Current Performance
-9.07%
Carisma therapeutics, inc.
-1.83%
Avg of Sector
-0.40%
S&P500
CARM Key Information
CARM Revenue by Segments
Browsing restrictions can be lifted for a fee.
CARM Net Income
Browsing restrictions can be lifted for a fee.
CARM Cash Flow
Browsing restrictions can be lifted for a fee.
CARM Profit Margin
Browsing restrictions can be lifted for a fee.
CARM PE Ratio River
Browsing restrictions can be lifted for a fee.
CARM Financial Forecast
Browsing restrictions can be lifted for a fee.
CARM Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
CARM Profile
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Price of CARM
CARM FAQ
When is CARM's latest earnings report released?
The most recent financial report for Carisma therapeutics, inc. (CARM) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CARM's short-term business performance and financial health. For the latest updates on CARM's earnings releases, visit this page regularly.
What is the operating profit of CARM?
According to the latest financial report, Carisma therapeutics, inc. (CARM) reported an Operating Profit of -9.33M with an Operating Margin of -250.31% this period, representing a growth of 52.16% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is CARM's revenue growth?
In the latest financial report, Carisma therapeutics, inc. (CARM) announced revenue of 3.73M, with a Year-Over-Year growth rate of 9.77%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does CARM have?
As of the end of the reporting period, Carisma therapeutics, inc. (CARM) had total debt of 2.33M, with a debt ratio of 0.15. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does CARM have?
At the end of the period, Carisma therapeutics, inc. (CARM) held Total Cash and Cash Equivalents of 7.74M, accounting for 0.49 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does CARM go with three margins increasing?
In the latest report, Carisma therapeutics, inc. (CARM) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -250.31%%, and net margin of -248.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CARM's profit trajectory and future growth potential.
Is CARM's EPS continuing to grow?
According to the past four quarterly reports, Carisma therapeutics, inc. (CARM)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.22. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of CARM?
Carisma therapeutics, inc. (CARM)'s Free Cash Flow (FCF) for the period is -9.54M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 57.48% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.